GlassScriptPhysician profile
Marisol C Clark
NPI 1578613030
$3,157.75
in general payments reported to CMS, 2019-2025
39 companies · $910 in 2025
The $910 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $209 · 2021: $338 · 2022: $268 · 2023: $230 · 2024: $946 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $688.10 | 2021-2025 | Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $333.14 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $279.25 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $246.14 | 2019-2025 | |
| Lilly USA, LLC | $183.62 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $158.11 | 2021-2025 | Veozah, Myrbetriq |
| Grifols USA, LLC | $127.23 | 2019-2025 | Prolastin-C Liquid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.77 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $96.00 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $90.92 | 2024-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.03 | 2020-2025 | Jardiance |
| Amgen INC. | $77.20 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $76.78 | 2024-2025 | Hetlioz, Fanapt |
| Ardelyx, INC. | $46.51 | 2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $38.49 | 2024-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisol Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.